everyone. morning, Good
corporate CollPlant prolong to medicine discuss call and technology financial on to is Collplant are XXXX developing lives. us products conference developments. join collagen and quarter second pleased today and very We results our improve to have you regenerative investor
industry. employees supporting innovation ecosystems science shareholders to the our more We in life are benefit medicine including stakeholders, our to leaders that and well sustainable patients, as as all becoming and regenerative the committed providing
programs. to And now, development on our
advanced we create of non-animal to through that Our organ medical proprietary goal and applying recombinant and products. our are novel use is novel technology solutions derived to collagen tissue human aesthetic
an from regenerative because is CollPlant this advancement CollPlant genetically derived tissue it it not animals. rhCollagen in Our recombinant due and human to – free, Instead tobacco properties which is is produces engineered products plants. collagen also both means xeno its
paradigm with In triggered the accordance second filler in payment long-term dermal dermal continues achievement milestone a the growth it in clinical market planned, a filler to its as top the for the tissue since candidate filler potential future program. and to achievement the milestone royalties shift to has to and product million product CollPlant. The with in the create quarter, in well AbbVie receive dermal properties fillers addition of the candidate advance soft product program the our AbbVie This provide we a tissue important as $XX is focus with would with development to announced skin payments as regenerative very phase the AbbVie in new its partner, and the filling. This CollPlant milestone collaboration filler. related has AbbVie. for to is of additional our company potential
is leading implants. program next breast regenerative Our our
animal milestones by end be we regenerative upcoming year a evaluate large our of will our One implants. initiating second to breast study
as animal infrastructure were This large first trial completion of study already soon announced to study. the the we look importantly, and events the the demonstrated That the formation year. result this no progressive follows implants neovascular and update within established maturing reported. stages have after adverse We months of forward in preclinical conclude of tissue as providing X with study, January regeneration of the as tissue highlighted study of an which by connective our networks
derived and biomaterials thus rhCollagen procedures blend patients for CollPlant’s response aesthetic are breast its alternative provide for without to of may breast regenerate expected and being collagen key recombinant period. revolutionary the implants that cancer and during reconstructive breast tissue immune post-mastectomy a are the other with proprietary of human eliciting our feature comprised reconstructive
quarter, of and second additive the the the we an our Initially, In a for project and announced industrial PXtechnology, a Stratasys, and will in the organs. human With with utilizing – implants. solution Collplant’s with related solution companies printer bioprinting solution collaborating in scale-up implants development Programmable for focus on technology. commercialization agreement of printing Stratasys to XD on scale are collaborative state-of-the-art important printing manufacturing development commercialization. This leader the world bioinks joint Stratasys, with clinical tissues biofabricate of collaboration leader and our XD collaborative we between development breast and effective Collplant’s will capabilities. regenerative regenerative support XD PhotoPolymerization trials to together unique DLP is Having that breast two be a combines rhCollagen-based the an
will differentiated than tissue companies accurately both technologies, have to that agreement, technologies human properties expected the Collplant’s properties. resolution and are and It and also scaffolds agreed and be that able regenerative will companies products. proprietary allow each fabrication. By of for bioprinted the have high cross print Other combined scalability mimic organs physical tissues combining to XD The other’s to Stratasys organ reproducibility. also promote possesses
DLP different which use the tissues or tissues bioinks technologies so It of best in example different suited technology our breast Here opportunity advanced use are of production with rate with printed organs for for implant different that are determine Collplant’s fabricating with optimal we in in the its our of to with that refine are was the fabricating organs. Stratasys we become such is may Collaborations formed Stratasys combination the gold you therefore with us bit important utilizing bioinks to properties. objective standard collagen-based can printer that and one accordance a our see types of as allow that an to bioinks.
have utilize to being strategy collaborations different multiple is previously, serve with printing As parties. we our technologies and we different indications therefore to have mentioned sold
we for gut-on-a-chip as multiple For of use applicability cardiology, have of and print models. business very to such lung-on-a-chip needs multiple to tissue be such aspect would to example, able as and products ophthalmology, our materials or The small in orthopedics. has bioprinting construct with need areas features
wide and As academic produce in interested XD such, to and remains in a several tissues and institutions and of develop Collplant company’s partnering technology looks organs rhCollagen bioprinting medical engaged therapeutics leaders range to applications. expertise in discussions with industry and the
this patients. Food to and we autoimmune efficacy have implant from a in from that and will and Reports be studies. back year. revolutionary XXX,XXX But generate tissue study Drug events safety potential the data to breast regulatory large look XXXX. are will to post-mastectomy used to implant our and symptoms U.S. implants eliciting therefore associated breast range both additional the implants development Administration, for reporting that We forward The to from animal XXXX clinical Americans between are According regenerate without currently large to have reported or alternative anaplastic development, aesthetic approximately Collplant lymphoma. upcoming cell and results including the to designed optimize support the future and next are implant immune reconstructive submissions important regenerative study the cancer become adverse and response procedures, breast breast for involving to
with that is this allow to emulate provide University the sciences. existed humans. options Collplant that the tissue Sheba mention Aviv predictive lead patient could of together in XD our would A response such we that Lastly, and device assay responses a the a disrupt to Medical other where medical factors drug as which identify to life targets to in area personalized intestine to gut-on-a-chip human is platform. drug we improved have metabolism developing is Tel have Center, outcomes therapeutic bioprinted to and personalize program, professionals opportunity designed traditionally will model and an the
devices Tissue-on-a-chip of comprised the compartments typically targeted structures channels the organ. chambers or that and of are recapitulate distinct
colitis. system is physiological high unique successfully the predictive multi-array The therapy Our provide be Recently, the in therapy structure XD from then intended system used evaluate geometry throughput using on support gut design epithelial mimics based chip by resolution its to scaffolds. platform. the ulcerative The to the screening. managed printing team Collplant rhCollagen patients cells human response high to BioInk in personalized grow gut to being a printed relevance can tissue suffering gut of developed the Collplant XD formulation. enhances
of areas animal you ESG of we use medicine, expect for drug line developments. existing is development models without program animals. much this approach in the we over initiatives. various improvement our that remind will personalized And In groundbreaking be this diagnosis also and This the could means of drug for with be use very patient sustainable a
for We received the has hope the gut-on-a-chip by rights the the exclusive steps this CollPlant regulatory on to commercialize the So end of to year. product. provide an program update approval, next
for in several with discussions technology partnering in applications. interested and therapeutic engaged the medical expertise industry remains CollPlant bioprinting CollPlant’s and in mentioned, As additional leaders XD
line part ecosystems, of made commitment environmental, wanted to social In ESG to and being or our with that we sustainable mission initiatives. support governance this highlight we to advance have
step to ESG expert quarter, lead to our first is dedicated which do in Our hiring implemented the was this, second effort.
CollPlant is areas our the already that in ESG mission. manager Our identifying responsible strengths are ESG in for with of line
Being able to and business look Importantly, our to forward this as day-to-day communicate operations we she on the identified relate relate and ESG as doing efforts to conducted us mandate our we a of these where communicate partners to being we our they practices or are with a can and able they current We our mission to company for further values communicating our culture. and was working to initiative improve. formal public. initiatives and analysis will as well what lead company both after correctly to operations
our This initial programs. about promising concludes very my remarks
provide the the Eran? will Deputy Rotem results. recap to and I Eran to of Officer, CEO Chief turn a our Now, call Financial financial over
